0
Abstract: Poster Presentations |

LONG-TERM SAFETY OF LEVALBUTEROL ADMINISTERED VIA METERED-DOSE INHALER IN PATIENTS WITH ASTHMA FREE TO VIEW

M. V. Parsey, MD, PhD*; A. D. D'Urzo, MD; M. G. Marcus, MD; K. Tripp; W. K. McVicar, PhD; R. A. Baumgartner, MD
Author and Funding Information

Sepracor Inc., Marlborough, MA



Chest. 2006;130(4_MeetingAbstracts):164S. doi:10.1378/chest.130.4_MeetingAbstracts.164S-b
Text Size: A A A
Published online

Abstract

PURPOSE: Examine the long-term safety of levalbuterol (LEV) HFA administered via metered dose inhaler (MDI) in patients with stable asthma.

METHODS: Mild-to-moderate asthmatics (mean FEV1 2.2L, 68.3% predicted) ≥12 years participated in a multicenter, parallel group, open-label study. After a 7-day QID single-blind placebo HFA MDI run-in, patients were randomized in a 2:1 ratio to equivalent doses of (R)-albuterol in LEV MDI (90 μg; 2 actuations of 45 μg (R)-albuterol; n=496) or racemic albuterol (RAC) MDI (180 μg; 2 actuations of 90 μg (R)-albuterol and 90 μg (S)-albuterol; n=250) for up to 52 weeks of QID dosing. The primary endpoint was the incidence of post-randomization adverse events (AEs). Asthma attacks, laboratory evaluations, electrocardiograms, and the % change in FEV1 from visit predose were also assessed.

RESULTS: The incidence of AEs was similar for LEV (72.0%) and RAC (76.8%). Rates of β2-mediated AEs were 18.8% and 25.6%, respectively. The incidence of serious AEs (3.6% and 5.2%, respectively) and discontinuations due to AEs (9.1% and 9.6%, respectively) were also similar. No deaths occurred. Rates of asthma AEs were 18.3% and 19.6%, respectively, and rates of asthma attacks were 16.3% and 18.4%. Small mean changes in potassium occurred in both groups (LEV: post-first dose −0.03 mEq/L, at 52 weeks −0.02 mEq/L; RAC: post-first dose −0.05 mEq/L; at 52 weeks −0.06 mEq/L). No statistically significant differences were noted at 52 weeks for changes in ventricular heart rate or QTc-F. Mean % changes in FEV1 one hour post-first dose were 18.1% and 16.3% for LEV and RAC, respectively; and 12.7% and 11.6% at week 52, respectively.

CONCLUSION: In this trial, LEV MDI administered as 90 μg QID for up to 52 weeks was generally well-tolerated.

CLINICAL IMPLICATIONS: Long-term treatment (up to one year) with LEV HFA MDI is well tolerated in patients with mild-to-moderate asthma, suggesting that it may be an appropriate treatment now available for use in the management of reversible airways obstruction. Support for this study provided by Sepracor Inc.

DISCLOSURE: M. Parsey, Employee Drs. Parsey, McVicar and Baumgartner, and Mr. Tripp, are employees of Sepracor Inc.; Consultant fee, speaker bureau, advisory committee, etc. Drs. Smith and Marcus are investigators for Sepracor Inc. Dr. Marcus has served on the Xopenex Speaker Bureau; Other Support for this study provided by Sepracor Inc.

Wednesday, October 25, 2006

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543